Toll-like receptor 3 (TLR3) overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  D. Chaussabel,et al.  TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons. , 2020, The Journal of clinical investigation.

[3]  K. Souček,et al.  Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance , 2020, Cancers.

[4]  M. Martí-Renom,et al.  CTCF is dispensable for immune cell transdifferentiation but facilitates an acute inflammatory response , 2020, Nature Genetics.

[5]  S. Lantuejoul,et al.  Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. , 2019, Cancer letters.

[6]  A. Haese*,et al.  Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer , 2019, Molecular oncology.

[7]  Christoph B. Messner,et al.  DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput , 2019, Nature Methods.

[8]  F. Cutruzzolà,et al.  Linking Infection and Prostate Cancer Progression: Toll-like Receptor3 Stimulation Rewires Glucose Metabolism in Prostate Cells , 2019, AntiCancer Research.

[9]  C. Petes,et al.  Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  A. Zoubeidi,et al.  Biological Evolution of Castration-resistant Prostate Cancer. , 2019, European urology focus.

[11]  Yayi Hou,et al.  Toll‐like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3‐UNC93B1‐IFN‐β signaling axis in paclitaxel‐resistant colon cancer , 2018, Journal of cellular physiology.

[12]  C. Chien,et al.  Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells. , 2018, Oral oncology.

[13]  T. Ou,et al.  The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer , 2018, Front. Immunol..

[14]  N. Sharifi,et al.  Androgen Signaling in Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[15]  T. Espevik,et al.  Surface TLR 3 expression in metastatic IECs 15410 , 2017 .

[16]  J. Pavelić,et al.  Toll‐like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF , 2017, Molecular carcinogenesis.

[17]  E. Wiemer,et al.  Loss of SLCO1B3 drives taxane resistance in prostate cancer , 2016, British Journal of Cancer.

[18]  Xuetao Cao,et al.  Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. , 2016, Cancer cell.

[19]  H. Klocker,et al.  Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide , 2016, Oncotarget.

[20]  A. Kozubík,et al.  Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells , 2015 .

[21]  L. Lands,et al.  Stimulation of the RIG-I/MAVS Pathway by Polyinosinic:Polycytidylic Acid Upregulates IFN-β in Airway Epithelial Cells with Minimal Costimulation of IL-8 , 2015, The Journal of Immunology.

[22]  S. Vowler,et al.  Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study , 2015, EBioMedicine.

[23]  E. Wiemer,et al.  Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. , 2015, European urology.

[24]  M. Kortylewski,et al.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients , 2015, Clinical Cancer Research.

[25]  A. Filippini,et al.  Transfected Poly(I:C) Activates Different dsRNA Receptors, Leading to Apoptosis or Immunoadjuvant Response in Androgen-independent Prostate Cancer Cells* , 2015, The Journal of Biological Chemistry.

[26]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[27]  A. Filippini,et al.  TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo , 2014, Journal of cellular and molecular medicine.

[28]  G. Sen,et al.  Tyrosine phosphorylation in Toll-like receptor signaling. , 2014, Cytokine & growth factor reviews.

[29]  C. Croce,et al.  Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression , 2013, Proceedings of the National Academy of Sciences.

[30]  J. Casanova,et al.  Cleaved/Associated TLR3 Represents the Primary Form of the Signaling Receptor , 2013, The Journal of Immunology.

[31]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[32]  Divyendu Singh,et al.  Proteolytic Processing Regulates Toll-like Receptor 3 Stability and Endosomal Localization* , 2012, The Journal of Biological Chemistry.

[33]  G. Sen,et al.  Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling , 2012, Science Signaling.

[34]  B. Mellado,et al.  Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[35]  L. Zitvogel,et al.  TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. , 2011, Cancer research.

[36]  F. Vizoso,et al.  Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence , 2011, Cancer Immunology, Immunotherapy.

[37]  Shereen R Kadir,et al.  Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells , 2010, Nature Cell Biology.

[38]  Y. Huang,et al.  Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells , 2010, Oncogene.

[39]  L. Battistini,et al.  TLR Stimulation of Prostate Tumor Cells Induces Chemokine-Mediated Recruitment of Specific Immune Cell Types , 2010, The Journal of Immunology.

[40]  G. Sen,et al.  High-Throughput Screening for TLR3–IFN Regulatory Factor 3 Signaling Pathway Modulators Identifies Several Antipsychotic Drugs as TLR Inhibitors , 2010, The Journal of Immunology.

[41]  P. Yaswen,et al.  A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.

[42]  R. de Wit,et al.  Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer , 2008, British Journal of Cancer.

[43]  A. Filippini,et al.  Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. , 2008, Carcinogenesis.

[44]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[45]  S. Cross,et al.  BMP‐6 over‐expression in prostate cancer is associated with increased Id‐1 protein and a more invasive phenotype , 2008, The Journal of pathology.

[46]  M. Feldmann,et al.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. , 2007, Blood.

[47]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[48]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[49]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[50]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[51]  E. Small,et al.  Immunotherapy for prostate cancer , 2006, Current urology reports.

[52]  Liqing Chen,et al.  Anti-tumor outcome evaluation against non-small cell lung cancer in vitro and in vivo using PolyI:C as nucleic acid therapeutic agent. , 2019, American journal of translational research.

[53]  R. Shah,et al.  HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. , 2017, Cancer research.

[54]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[55]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.